102 related articles for article (PubMed ID: 17822885)
1. Evidence that lithium protects against tardive dyskinesia: the Curaçao Extrapyramidal syndromes study VI.
van Harten PN; Hoek HW; Matroos GE; van Os J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):152-5. PubMed ID: 17822885
[TBL] [Abstract][Full Text] [Related]
2. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
van Harten PN; Hoek HW; Matroos GE; van Os J
J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
[TBL] [Abstract][Full Text] [Related]
3. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.
Damier P; Thobois S; Witjas T; Cuny E; Derost P; Raoul S; Mertens P; Peragut JC; Lemaire JJ; Burbaud P; Nguyen JM; Llorca PM; Rascol O;
Arch Gen Psychiatry; 2007 Feb; 64(2):170-6. PubMed ID: 17283284
[TBL] [Abstract][Full Text] [Related]
4. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study.
Tenback DE; van Harten PN; Slooff CJ; van Os J;
Compr Psychiatry; 2007; 48(5):436-40. PubMed ID: 17707251
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
Ulrich S; Sandmann U; Genz A
Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
[TBL] [Abstract][Full Text] [Related]
6. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group.
van Os J; Walsh E; van Horn E; Tattan T; Bale R; Thompson SG
Acta Psychiatr Scand; 2000 Apr; 101(4):300-6. PubMed ID: 10782550
[TBL] [Abstract][Full Text] [Related]
7. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
Glazer WM; Morgenstern H; Doucette JT
J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
[TBL] [Abstract][Full Text] [Related]
8. Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics.
Rittmannsberger H
Psychiatr Danub; 2008 Dec; 20(4):461-5. PubMed ID: 19011586
[TBL] [Abstract][Full Text] [Related]
9. Clinical and familial correlates of tardive dyskinesia in India and Israel.
Bhatia T; Sabeeha MR; Shriharsh V; Garg K; Segman RH; Uriel HL; Strous R; Nimgaonkar VL; Bernard L; Deshpande SN
J Postgrad Med; 2004; 50(3):167-72; discussion 172. PubMed ID: 15377799
[TBL] [Abstract][Full Text] [Related]
10. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.
Gharabawi GM; Bossie CA; Lasser RA; Turkoz I; Rodriguez S; Chouinard G
Schizophr Res; 2005 Sep; 77(2-3):119-28. PubMed ID: 15913963
[TBL] [Abstract][Full Text] [Related]
11. Tardive dyskinesia: determinants of temporal dynamics of its emergence.
Latalova K
Neuro Endocrinol Lett; 2008 Dec; 29(6):995-8. PubMed ID: 19112392
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up.
Licht RW; Vestergaard P; Brodersen A
Bipolar Disord; 2008 Feb; 10(1):79-86. PubMed ID: 18199244
[TBL] [Abstract][Full Text] [Related]
13. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam in tardive dyskinesia.
Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
[TBL] [Abstract][Full Text] [Related]
15. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
Nasrallah HA
Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
[TBL] [Abstract][Full Text] [Related]
16. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
Dean CE; Kuskowski MA; Caligiuri MP
J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
[TBL] [Abstract][Full Text] [Related]
17. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients.
Mur M; Portella MJ; Martínez-Arán A; Pifarré J; Vieta E
J Clin Psychiatry; 2008 May; 69(5):712-9. PubMed ID: 18435565
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
Lee JG; Shin BS; Lee YC; Park SW; Kim YH
Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
[TBL] [Abstract][Full Text] [Related]
19. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.
Kang SG; Lee HJ; Choi JE; An H; Rhee M; Kim L
Hum Psychopharmacol; 2009 Jan; 24(1):55-60. PubMed ID: 19051221
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
Miodownik C; Meoded A; Libov I; Bersudsky Y; Sela BA; Lerner V
Clin Neuropharmacol; 2008; 31(4):197-203. PubMed ID: 18670243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
